Cancer genomics company Exelixis announced on Monday that it would cut 270 jobs, a loss of about 40% of its workforce, with the brunt of the cuts aimed at drug discovery, according to a Securities and Exchange Commission filing. Image: Donovan Govan/WikimediaThe company, which is using genomic models of cancer to screen a massive library of compounds, estimates the layoff and subsequent restructuring will save $90 million through 2011. Last year __The Scientist__ profiled the company's linkurl:
 |
The liquid world of fetal development provides a rich source of nutrition and protection tailored to meet the needs of the growing fetus.
View this Issue
In this webinar, Andre Mueller will discuss how scientists characterize therapeutic proteins in different formulations and spot the effects of excipients on protein stability.
A streamlined, automated process helps scientists coordinate site-ready production-level whole genome sequencing results.
In this webinar, learn how scientists are using cutting-edge spatial proteomics technologies to advance their understanding of cellular organization in healthy and diseased tissues.
Scientists rely on cytokines, growth factors, and other agents to direct and create different types of organoid models.
System strengthens Taiwan’s capabilities in protein drug discovery research
The Transferpette® pro expands the Transferpette® family, offering scientists even greater flexibility to match their pipetting preferences and workflow requirements.
Fast, gentle, and highly specific glycoprotein labeling compatible with downstream immunofluorescence, enabled by next-generation aminooxy chemistry.
Thermo Scientific X and S Series General Purpose Centrifuges are designed to help provide exceptional performance, versatility and enhanced sustainability.
